Marvel Biosciences secures investment from 5 Horizons

Marvel Biosciences has announced a significant financial and strategic investment from 5 Horizons Ventures. This backing will be instrumental in supporting the company's upcoming Phase 1 clinical trial for its lead asset, MB-204. The investment underscores confidence in Marvel's proprietary technology and its potential to address unmet medical needs. The partnership with 5 Horizons Ventures is expected to accelerate the development timeline and pave the way for future clinical advancements.